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The pandemic of obesity is associated with parallel epidemics
of sleep disorders, diabetes, hypertension, and cardiovascular
disease (CVD), that is, the primary cause of morbidity
and mortality among adults [1]. Sleep disorders generally
go unrecognized and undiagnosed and appear to play a
major role in the interrelationships between obesity, diabetes,
hypertension, and cardiovascular disease [2–4]. Accumu-
lating evidence from cross-sectional as well as longitudinal
studies by various groups, including ours, indicates close
interrelationships among sleep disorders and diabetes, hyper-
tension, and CVD including stroke, coronary artery disease,
and heart failure, particularly among minority populations
and women [2–5]. Postulated mechanisms or mediators of
interrelationships between sleep disorders and CVD include
oxidative stress, increased inflammation, increased uric acid
endothelial dysfunction, dyslipidemia, and hypercoagulabil-
ity, which are common underlying CVD risk factors among
individuals with metabolic syndrome [6–8]. Furthermore,
the cost of undiagnosed sleep disorders appears to be
exceedingly high, prompting the AmericanAcademy of Sleep
Medicine to recommend screening for at-risk individuals [9,
10]. This is quite important giving the mounting evidence of
decreasedCVD risk and improved cardiometabolic functions
with treatment of sleep disorders, particularly among patients
with sleep apnea [9].
In this special issue, we assembled a group of world-
renowned editors with complementary expertise in sleep
medicine, hypertension, diabetes, obesity, and cardiovascular
disease to lead this initiative. Commensurate with level
of expertise of the editorial team, we were able to attract
important papers from established investigators from all over
the world. Judging from the accepted papers for this special
issue, we surmise that they are both topical and timely and
they are likely to have a significant impact on the field.
The issue covers a wide range of topics, from dietary
interventions, in the form of low glycemic index food and its
effectiveness in lowering blood pressure to factors associated
with medication nonadherence among hypertensives in two
African countries: Ghana and Nigeria. Another important
topic covered is the implications of renal denervation, a rather
novel and increasingly studied potential therapy for hyper-
tension, in patients with sleep apnea. An interesting topic
also examined in a research paper indicated that in Black
Americanworking nonday time shift aremore likely to report
hypertension, especially with short sleep duration. This arti-
cle opens further questions for investigations including those
examining the underlying mechanisms for these findings.
This special issue also included an epidemiologic assessment
for the prehypertension and hypertension in two countries in
Sub-Saharan Africa.This study assessed predictors of various
stages of hypertension including obesity and educational
levels in these vulnerable populations. Another closely related
article fromAfrica among people with hypertension assessed
the subtypes of hypertension in different light including
Hindawi Publishing Corporation
International Journal of Hypertension
Volume 2015, Article ID 197534, 2 pages
http://dx.doi.org/10.1155/2015/197534
2 International Journal of Hypertension
controlled hypertension, isolated systolic hypertension, and
isolated diastolic hypertension as well as systolic-diastolic
hypertension as they relate to obesity. This is quite impor-
tant since different subtypes confer various degrees of risk.
For example, among Blacks and/or people with diabetes
systolic hypertension is predominant and is associated with
high CVD risk factors including microalbuminuria, insulin
resistance, postural hypertension, salt sensitivity, and volume
expansion. Characterization of subtypes of hypertension not
only opens the doors for further investigations of research
questions, but also helps strategize in terms of treatment such
as the utilization of low salt diet, diuretics, and agents that
inhibit the renin angiotensin aldosterone function (RAAS),
such as Angiotensin Converting Enzyme (ACE) Inhibitors
and the Angiotensin Receptor Blockers (ARBs).
Finally, the interrelationships between sleep disorders
and CVD are explained and illustrated in a well-written
review article included in this issue that highlights the most
recent findings and insights in this highly complex topic, pro-
viding the readers with food for thought that will hopefully
generate testable and clinically important hypotheses.
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